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Abstract
Background: The choice of appropriate artemisinin-based combination therapy depends on several factors (cost,
efficacy, safety, reinfection rate and simplicity of administration). To assess whether the combination
dihydroartemisinin-piperaquine (DP) could be an alternative to artemether-lumefantrine (AL), the efficacy and the
tolerability of the two products for the treatment of uncomplicated falciparum malaria in sub-Saharan Africa have
been compared.
Methods: A multicentric open randomized controlled clinical trial of three-day treatment of DP against AL for the
treatment of two parallel groups of patients aged two years and above and suffering from uncomplicated
falciparum malaria was carried out in Cameroon, Côte d’Ivoire and Senegal. Within each group, patients were
randomly assigned supervised treatment. DP was given once a day for three days and AL twice a day for three
days. Follow-up visits were performed on day 1 to 4 and on day 7, 14, 21, 28 to evaluate clinical and
parasitological results. The primary endpoint was the recovery rate by day 28.
Results: Of 384 patients enrolled, 197 were assigned DP and 187 AL. The recovery rates adjusted by genotyping,
99.5% in the DP group and 98.9% in the AL group, were not statistically different (p = 0.538). No Early Therapeutic
Failure (ETF) was observed. At day 28, two patients in the DP group and five in AL group had recurrent
parasitaemia with Plasmodium falciparum. In the DP group, after PCR genotyping, one of the two recurrences was
classified as a new infection and the other as recrudescence. In AL group, two recurrences were classified after
correction by PCR as recrudescence. All cases of recrudescence were classified as Late Parasitological Failure (LPF).
In each group, a rapid recovery from fever and parasitaemia was noticed. More than 90% of patients did no longer
present fever or parasitaemia 48 hours after treatment. Both drugs were well tolerated. Indeed, no serious adverse
events were reported during the follow-up period. Most of the adverse events which developed were moderate
and did not result in the treatment being stopped in either treatment group.
Conclusions: Dihydroartemisinin-piperaquine was as effective and well-tolerated as artemether-lumefantrine in the
treatment of uncomplicated falciparum malaria. In addition, dihydroartemisinin-piperaquine, a single daily dose,
could be an advantage over artemether-lumefantrine in Africa because of better treatment observance.
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Malaria caused by Plasmodium falciparum is a serious
concern for public health and development in Africa.
The most part of the continent is facing increasing
resistance of this parasite to chloroquine and sulphadox-
ine-pyrimethamine, the widely available and cheap anti-
malarial drugs. In order to overcome this resistance pro-
blem, several African countries have recently adopted
artemisinin-based combination therapy (ACT) as first-
line treatment for uncomplicated malaria [1,2]. The
artemether-lumefantrine (AL) combination proved to be
highly effective and well-tolerated in several studies in
Africa [3-5]. However, a twice daily dose schedule of AL
and its need to be administered together with a fat-rich
meal [6] are a disadvantage.
Dihydroartemisinin-piperaquine (DP) is a new ACT
administered as single daily dose that has proved to be
well tolerated and highly effective against uncomplicated
falciparum malaria in southeast Asia [7-12] and in east-
ern Africa [13,14]. However, no clinical trial concerning
this anti-malarial drug has yet been conducted in western
and central Africa. Therefore, a randomized non-inferior-
ity open trial has been carried out to compare efficacy
and tolerability of DP to that of AL, the reference ACT,
in the treatment of uncomplicated falciparum malaria in
Cameroon, Côte d’Ivoire and Sénégal. The hypothesis
was that DP is as efficacious and safe as AL.
Methods
Study site and population
This study was carried out from November 2006 to May
2008 in three sub-Saharan countries: Senegal and Côte
d’Ivoire are in western Africa, Cameroon is in central
Africa. In Cameroon, the study took place at the Univer-
sity Hospital Centre. In Côte d’Ivoire, it took place at
the health care centre of Bocabo, which is located in
Abobo in the north of Abidjan (the economic capital).
In Senegal, the assessment took place at the health care
centre of Darou Marnane in the sanitary district of
Touba, which is located in the centre of the country at
200 km of Dakar.
The study population consisted of outpatients visiting
health care centres for uncomplicated falciparum
malaria-like symptoms. Patients were enrolled if they
meet the following selection criteria: 1) at least two
years old; 2) fever with axillary temperature > or = 37.5°
C; 3) P. falciparum mono-infection with a parasitaemia
from 2,000 to 200,000/μl of blood, in Cameroon and
Côte d’Ivoire, and from 1,000 to 100,000/μl of blood in
Sénégal; 4) provision of the written and informed con-
sent by the patient or his legal guardian for children; 5)
no history of previous serious side-effects to the drugs
used in the trial; 6) no evidence of a concomitant febrile
illness; 7) no danger signs or evidence of severe malaria;
8) no treatment with 4-amino quinoleines, sulphadox-
ine-pyrimethamine, mefloquine or halofantrine in the
previous seven days, or with quinine, artemisinin or
cyclins in the previous three days, 9) no pregnancy or
nursing; 10) no ongoing anti-malarial treatment.
The number of patients to be enrolled was determined
by Epi Info 2000 software. The estimated expected
recovery rate with AL was 98%, with a maximum accep-
table difference of 5% to conclude that DP was non-
inferior and a power of 85%. The minimum number of
people to be included in each arm was calculated from
these assumptions to be 180 patients. Assuming a 5%
loss to follow up the overall final target sample size of
380 participants was estimated.
Study design and treatment
This study was a randomized, controlled and open ther-
apeutical trial of DP against AL as the reference treat-
ment. The three criteria of judgment were clinical
efficacy, biological efficacy and tolerance. The study pro-
tocol was first approved in each country by the National
Ethical Committee according to protocols and standards
operating procedures of Good Clinical Practices of the
ICH harmonized Triplicate Guide Lines for Good Clini-
cal Practice made in 1996 and the Helsinki Declaration
on human being research. This approval was critical for
the study start.
For each patient who met inclusion criteria, the proto-
col was read and explained to him/her or the legal guar-
dian (for children) who in case of acceptance had to
sign the written informed sheet afterward to authorize
recruitment of the child in the study. The patient or
guardian was given a copy of the informed consent and
patient information sheet. For patients who gave their
consent, baseline examinations and laboratory investiga-
tions were carried immediately free of charge. Those of
patients who met inclusion criteria at baseline (day 1)
were randomly assigned to one of the two treatment
groups following a randomization list. In each study site
computer generated randomization codes were prepared
by an independent individual. These codes were
enclosed in sequentially numbered opaque sealed envel-
opes, each of which contained the treatment allocation.
The envelopes were assigned in sequential order to par-
ticipants after inclusion.
Treatments in the two groups were allocated accord-
ing to body weight. First patient group was allocated
dihydroartemisinin-piperaquine (DP) (Duocotecxin
® )
(Beijing Holley-Cotec Pharmaceutical Co. Ltd, China)
once daily for three consecutive days. Each tablet of DP
contains 40 mg of dihydroartemisinin and 320 mg of
piperaquine. DP treatments varied as follows: patients
between 5-9 kg received half a tablet per dose, those
between 10-14 kg 3/4 tablet, 15-19 kg 1 tablet per dose,
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per dose, 30-34 kg 1 tablet + 3/4 per dose, 35-39 kg 2
tablets per dose, 40-44 kg 2 tablets + 1/4 per dose, 45-
49 kg 2 tablets + 1/2 per dose and patients ≥ 50 kg 3
tablets per dose. The second patient group was allocated
artemether-lumefantrine (AL) (Coartem
® )t a b l e t s
(Novartis Pharma, Switzerland), each tablet containing
20 mg artemether and 120 mg lumefantrine. Patients
received treatment dose according to the following
scheme: i.e. patients between 5-14 kg received one tablet
per dose, those between 15-24 kg two tablets, those
between 25-34 kg received three tablets per dose and
those with body weight ≥ to 35 kg received four tablets
per dose. Doses were given at T0h, T8h, T24h, T36h,
T48h and T60h. All treatments were given under direct
supervision of the study co-investigators. If the patient
vomited within thirty minutes after drug administration,
the whole dose was re-administered. If the vomiting per-
sisted, the patient was excluded from the study and
referred to the health centre doctor for management
according to the current national policy. The dose could
not be administered again if vomiting occurred more
than 60 minutes after administration.
After inclusion, the patient had to come to follow-up
visits during which clinical and physical examinations as
well as laboratory investigations were carried out by the
physician and laboratory technicians.
Efficacy and tolerance
Clinical and biological efficacies were assessed using the
WHO in vivo test with a follow-up period of 28 days
[14,15]. At enrollment (day 1) as well as follow-up visits,
a full clinical and physical examination was performed;
data were recorded in a case report form. Laboratory
investigations for P. falciparum stages and loads were
also carried out at baseline and follow-up visits by
means of finger pricking for thin and thick smears. Fol-
low-up visits were on day 2, day 3, day 4, day 7, day 14,
day 21 and day 28 after the first anti-malarial drug had
been swallowed. Finger prick blood samples were col-
lected for microscopy. Blood samples were also collected
for P. falciparum molecular biology analysis at baseline
and then after day 7 in case of positive parasitaemia to
check if parasitaemia recurred in patients. Response to
treatment was measured and defined according to
WHO guidelines [15]. Other blood samples were col-
lected by venipuncture at baseline and day 4 for the
measurement of haemoglobin levels and biochemical
parameters, such as bilirubin, creatinin and transami-
nases (AST, ALT). Patients developing danger signs dur-
ing follow-up visits were withdrawn from the study,
referred to the appropriate hospital ward for care and
medication. Other patients showing complications or
treatment failure were also referred for appropriate care
and medication but remained in the study for the fol-
low-up. Adverse events (AE) were recorded on the case
report forms and their gravity was graded as mild, mod-
erate or severe. An AE was defined as an unfavourable
and unintended symptom, sign or disease.
Parasite clearance and gametocyte dynamics
Plasmodium falciparum parasite clearance was assessed
microscopically. For this, Giemsa-stained thick and thin
blood smears were prepared according to WHO guide-
lines [15]. Two independent, experienced microscopists,
examined the smears for the presence and quantification
of parasites species.
Genotyping
In order to distinguish re-infection (RI) from recrudes-
cence (RE), merozoite surface protein 1 and 2 (msp1
and msp2) genotyping was performed as described by
Faye [16] on dried blood spots collected at the patient
enrollment (day 1) and at the time when parasitaemia
reccurrence was noticed. Blood spots were collected on
Whatman filter paper (Whatman International Ltd.
M a i d s t o n e ,U K )a n da i r - d r i e da tr o o mt e m p e r a t u r ef o r
PCR analysis. DNAwas extracted using the methanol
method [17]. Molecular biology analysis was performed
at the Parasitology Laboratory of Cheikh Anta Diop
University (Dakar, Sénégal).
End points
The primary end point was the recovery rate by 28,
defined as the percentage of patients who had an ade-
quate clinical and parasitological response (ACPR) after
follow-up for 28 days. Efficacy was evaluated using a
modified intention to treat analysis, which included the
379 patients, randomized and not lost to follow-up. The
secondary end points were the incidence of early clinical
failure (ECF), late parasitological failure (LPF), late clini-
cal failure (LCF), change in gametocyte carrier status,
fever and parasites clearance and adverse clinical and
laboratory events.
Statistical analysis
All data were recorded and checked using Epi data ver-
sion 3.1 and analysed with SPSS for windows (version
12.0). Patient’s characteristics of the two groups at
inclusion were compared using Pearson’sC h i - 2t e s t ,
independent samples t test or Mann-Whitney test. The
modified intention to treat analysis was performed using
Kaplan-Meier survival analysis with log rank testing the
treatment failures distribution function. The cases of
protocol violation and withdrawn consent were censored
at the time they left the study. The distributions of fever
and parasite clearance were compared using Pearson’s
Chi-2 test. Differences of haemoglobin and biochemical
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D4 were computed. Changes in haemoglobin concentra-
tions and in biochemical parameters were compared
using the paired t test. The level of significance for sta-
tistical tests was set at 0.05.
Results
Global distribution and baseline characteristics of
patients in the study
A total of 384 patients were included in the study. 197
patients were randomized to DP and 187 to AL. In the
DP group, six patients were excluded after enrollment.
Of these, four patients were lost during follow-up and
one case of protocol violation (self-medication with
another anti-malarial drug) and one case of withdrawal
of consent were noticed. In the AL group, four patients
were excluded during the follow-up: one patient was
lost sight. There were one case of protocol violation and
two cases of withdrawal of the consent.
Finally, 191 patients and 183 patients were successfully
followed up, respectively in DP and AL groups (Figure 1).
Baseline characteristics of patients receiving either AL or
DP are presented in Table 1 and Table 2. There were no
statistically significant differences in distribution by sex
or age band. Average temperatures in the two treatment
groups were not statistically different. There were also no
statistically significant differences between any of the
laboratory parameters. Both groups were, therefore, con-
sidered statistically equivalent at inclusion.
Clinical and parasitological outcomes
Kaplan-Meier estimates of recovery rates unadjusted by
genotyping were 99.0% in the DP group and 97.3% in
the AL group. There was no statistical difference
between the two groups (p = 0.230). These recovery
rates adjusted by genotyping, 99.5% in the DP group
and 98.9% in the AL group, were not statistically differ-
ent (p = 0.538). There was no significant study site
effect on these estimates.
No Early Therapeutic Failure (ETF) was observed. At
day 28, 2 patients in the DP group and 5 in AL group
had recurrent parasitaemia with P falciparum. In the DP
group, after PCR genotyping, one of the two recurrences
was classified as a new infection and the other as recru-
descence. In AL group, two recurrences were classified
after correction by PCR as recrudescence. All cases of
recrudescence were classified as Late Parasitological
Failure (LPF).
 
 
 
 
 
 
 
 
 
 
 
 
 
Cameroon:     104 
Côte d’Ivoire:    146 
Senegal:    134 
DP Arm  
197 
AL Arm  
187 
Full follow-up  
191 
Full follow-up 
183 
-4 lost to follow-up  
-1 case of protocol violation 
-1 withdrawn consent  
-1 lost to follow-up  
-1 case of protocol violation 
-2 withdrawn consents  
Cameroon:     56 
Côte d’Ivoire:    73 
Senegal:    62 
Cameroon:     48 
Côte d’Ivoire:    70 
Senegal:    65 
Patients randomized: 
384 
Figure 1 Global distribution of patients in the study.
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parasitaemia within 48 hours after enrollment; there was
no statistical difference between the two groups (p =
0.866) (Figure 2). Fever clearance was equally high: at
day 3 almost all patients were apyretic, with no differ-
ence between the 2 groups (p = 0.94) (Figure 3). At
inclusion, there were only eight gametocyte carriers in
the DP group and six in the AL group. The number of
gametocyte carriers decreased to one on day 3 in the
DP group and to two in the AL group. From day 4,
there were no more gametocyte carriers in both groups.
Adverse events
Among the 384 patients followed, 35 (23 in DP group
and 12 in AL group) had adverse events (9.1%). There
was no severe adverse event in the two groups and no
treatment was interrupted due to adverse events. Most
of adverse events were of moderate severity. The most
commonly reported adverse events in both treatment
groups were abdominal pain, dizziness, diarrhoea,
vomiting, pruritus and nausea (Table 3). Adverse events
were not significantly different between the two treat-
ment groups.
A decrease of haemoglobin values was observed from
the beginning of treatment to day 4. This decrease was
more important in AL group (0.36 g/dl) than DP group
(0.14/g/dl). The decrease was significant in AL group (p
= 0.001) but not in DP group (p = 0.221). In DP group
from the beginning of the treatment to day 4, there was
a decrease of the mean of AST and a small increase of
ALT mean, while in the AL group, AST and ALT
means increased. However, these variations were not
significantly different. The decrease of the mean of crea-
tinin from the beginning of the treatment to day 4 was
not significant in the DP group but was significant in
the AL group. In the two groups, the bilirubin decrease
was significant (Table 4).
Discussion
In this study, the efficacy and tolerability of two ACT
formulations have been compared in a randomized trial
of patients with uncomplicated malaria and followed up
for 28 days. Both treatments were highly efficient and
Table 1 Comparison of the two treatment groups at inclusion
DP AL p*
Numbers 197 187
Sex
M, n (%) 97 (49.2) 93 (47.2) 0.923**
F, n (%) 100 (50.8) 94 (52.8)
Mean age (SD) years 15.64 (14.22) 13.48 (12.64) 0.117
[2 - 5[, n (%) 34 (17.3) 44 (23.7)
[5 - 15[, n (%) 92 (46.7) 83 (44.6)
[15-77], n (%) 71 (36.0) 59 (31.7)
Mean temperature (SD) °C 38.42 (0.64) 38.43 (0.73) 0.887
[37.5 - 38.5[, n (%) 114 (57.9) 113 (60.4)
[38.5 - 41.0], n (%) 83 (42.1) 74 (39.6)
Median parasitaemia tpz/μl 10840 16000 0.546§
Min - Max 1000 - 200000 1000 - 200000
Gametocyte carrier rate, n (%) 8 (4.1) 6 (3.2) 0.649**
Mean AST (SD) IU/l 26.64 (15.53) 31.1 (29.08) 0.065
Mean ALT (SD) IU/l 18.71 (12.71) 24.06 (36.63) 0.061
Mean creatinin (SD) mg/l 6.79 (2.41) 6.76 (2.47) 0.915
Mean bilirubin (SD) mg/l 10.43 (7.21) 11.4 (8.65) 0.236
Mean haemoglobin (SD) g/dl 10.79 (2.06) 10.67 (2.12) 0.575
*Independent samples t test **Pearson’s Chi-2 test §Mann-Whitney test
Table 2 Clinical signs of patients at inclusion
DP (n, %) AL (n, %) Total n (%)
Fever 197 (100%) 187 (100%) 384 (100)
Headache 167 (84.8%) 153 (81.8%) 320 (83.3)
Asthenia 153 (81.8%) 106 (56.7%) 223 (58.1)
Anorexia 103 (52.3%) 95 (50.8%) 198 (51.6)
Shiver 93 (47.2%) 80 (42.8%) 173 (45.1)
Joint pain 77 (39.1%) 75 (40.1%) 152 (39.6)
Abdominal pain 35 (17.8%) 43 (23%) 78 (20.3)
Insomnia 18 (9.1%) 23 (12.3%) 41 (10.7)
Dizziness 18 (9.1%) 13 (6.9%) 31 (8.1)
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Figure 2 Parasite clearance.
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Figure 3 Fever clearance.
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Page 6 of 8well tolerated as previously described [1]. Moreover, sev-
eral studies with a follow-up of 42 days have been car-
ried out about the efficacy and tolerability of DP and
AL and all showed very good results [18-21]. The rate
of true recrudescence with P. falciparum was less than
5% in both treatment groups, and most P. falciparum
recurrences were caused by reinfection. These outcomes
are in accordance with previous efficacy studies of AL
[13,23] and DP [7,9,11,24,25].
The fact that there was more reinfection than recru-
descence shows that malaria transmission is very high in
t h e s ea r e a s( e s p e c i a l l yi nC ô t ed ’Ivoire and Cameroon).
Thus, even if anti-malarial drugs are effective and well-
tolerated, it is very important to continue to use preven-
tion tools, such as long-lasting insecticide-treated nets
to fight malaria.
The haemoglobin rate decrease was significant in
the AL group, but not in the DP group. This result
suggests that convalescence is obtained faster in the
DP group. However, as these data were obtained only
four days after enrollment, it would be more signifi-
cant to assess the haemoglobin rate decrease over 28
days. As in several studies which reported good
tolerance of DP [25,26] and AL [26], there were no
serious adverse events during the follow-up in the
assessment.
In conclusion, DP presented good and equivalent effi-
cacy and tolerability profile as AL. Therefore, DP is a
good alternative for the first-line treatment of uncompli-
cated P. falciparum malaria in endemic regions. Its once
daily dose is even more a significant advantage because
it could contribute to improve the patient’s treatment
compliance.
List of abbreviations
DP: combination Dihydroartemisinin - Piperaquine phosphate; AL:
Artemether - Lumefantrine.
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